Dergiler / Marmara Medical Journal / 2002 / Cilt: 15 - Sayı: 3

GEMCITABINE-ASSOCIATED REVERSIBLE ENCEPHALOPATHY A CASE REPORT

Sayfa
180–182
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

patient with metastatic Ewing's sarcoma who developed encephalopathy after treatment with gemcitabine, and his rapid recovery after discontinuation of the drug.Key Words: Gemcitabine, Neurotoxicity, Pediatric cancer

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:patient with metastatic Ewing's sarcoma who developed encephalopathy after treatment with gemcitabine, and his rapid recovery after discontinuation of the drug.Key Words: Gemcitabine, Neurotoxicity, Pediatric cancer
📊
Temel Bulgular & Veri:patient with metastatic Ewing's sarcoma who developed encephalopathy after treatment with gemcitabine, and his rapid recovery after discontinuation of the drug.Key Words: Gemcitabine, Neurotoxicity, Pediatric cancer
💡
Sonuç & Katkı:patient with metastatic Ewing's sarcoma who developed encephalopathy after treatment with gemcitabine, and his rapid recovery after discontinuation of the drug.Key Words: Gemcitabine, Neurotoxicity, Pediatric cancer
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Abstract

patient with metastatic Ewing's sarcoma who developed encephalopathy after treatment with gemcitabine, and his rapid recovery after discontinuation of the drug.Key Words: Gemcitabine, Neurotoxicity, Pediatric cancer

🔖

Bu Makaleye Atıf Yap

BERRAK, S. G., SOYSAL, A., TÜRKKAN, E., CANPOLAT, C. (2002). GEMCITABINE-ASSOCIATED REVERSIBLE ENCEPHALOPATHY A CASE REPORT. Marmara Medical Journal, Cilt: 15 - Sayı: 3, 180–182. https://ajindex.com/articles/284173

Kaynakça (5)

  1. Pavlakis N, Bell DH, Millward MJ, et al. Ratal pulmonary toxicity resulting from treatment with gemcitabine. Cancer 1997; 80: 286-291. Green MR. Gemcitabine safety overview. Semin Oncol 1996; 23: S32-S35. Gemzar product labeling. Indianapolis, IN, Eli Lilly and Company, March 1997.
  2. Hinchey J, Chaves C, Appignani B, et al. /I reversible posterior leukoencephalopathy syndrome. N Eng! J Med 1996; 334: 494-500.
  3. Ay H, Buonannao F, Schaefer F, et al. Posterior leukoencephalopathy without severe hypertension. Utility of diffusion- weighted MRI. Neurology 1998; 51: 1369- 1376. Vaughn D, Jarvik J, Hackney D, el al. High- dose cytarabine neurotoxicity. MR findings during the acute phase. Am J Neuroradiol 1993; 14: 1014-1016.
  4. Rontos HA, Wei EP, Deitrich D. Mechanism of cerebral arteriolar abnormalities after acute hypertension. Am J Physiol 1981; 240: 511- 527. Oelanty N, Vaughan C, Frucht S, Stubgen P. Erythropoe tin-associated hypertensive posterior leukoencephalopathy. Neurology 1997; 49: 686-689. lilion AD, Kallesen J, Cow! CT, et al. Ceftazidime-related nonconvulsive status epilepticus. Arch Intern Med 1994; 154: 586- 589. Herishanu YO, Zlotnik M, Mostoslavsky M, et al. Cufuroxime-induced encephalopathy. Neurology 1998; 50: 1873-1875.
  5. Jallon P, Fankhauser L, Du Pasquier R, Coeytaux A. Severe but reversible encephalopathy associated with cefepime. Neurophysiol Clin 2000; 30: 383-386.